The present invention specifically provides amorphous forms and crystalline complexes of SGLT2 inhibitors as novel materials in pharmaceutically acceptable form. The crystalline forms of the SGLT2 inhibitor canagliflozin are referred to as forms CS1, CS2, CS3, CS4 and CS5.本発明は、特に、薬学的に許容される形態の新規な材料としてSGLT2阻害剤の非結晶形態および結晶複合体を提供する。SGLT2阻害剤カナグリフロジンの結晶形態を、形態CS1、CS2、CS3、CS4およびCS5と呼ぶ。